Skip to main content

Published locations for Drug combo disappoints as second-line therapy for advanced NSCLC with EGFR and T790M mutations

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Drug combo disappoints as second-line therapy for advanced NSCLC with EGFR and T790M mutations

User login

  • Reset your password
  • /content/drug-combo-disappoints-second-line-therapy-advanced-nsclc-egfr-and-t790m-mutations
  • /oncologypractice/article/240822/lung-cancer/drug-combo-disappoints-second-line-therapy-advanced
  • /hematology-oncology/article/240822/lung-cancer/drug-combo-disappoints-second-line-therapy-advanced
  • /chestphysician/article/240822/lung-cancer/drug-combo-disappoints-second-line-therapy-advanced-nsclc